122 related articles for article (PubMed ID: 38691509)
21. Why aren't Australian pharmacists supplying naloxone? Findings from a qualitative study.
Olsen A; Lawton B; Dwyer R; Taing MW; Chun KLJ; Hollingworth S; Nielsen S
Int J Drug Policy; 2019 Jul; 69():46-52. PubMed ID: 31078908
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of naloxone furnishing community pharmacies in San Francisco.
Nguyen AM; Kearney TE; Apollonio DE
J Am Pharm Assoc (2003); 2020; 60(6):1050-1057.e1. PubMed ID: 32948461
[TBL] [Abstract][Full Text] [Related]
23. Socio-ecological and pharmacy-level factors associated with buprenorphine stocking at pharmacies in New York City.
Marotta PL; Abbas BT; Stringer K; Huang D; Schnaidt J; Goddard-Eckrich D; El-Bassel N; Gilbert L
Int J Drug Policy; 2021 Nov; 97():103321. PubMed ID: 34358803
[TBL] [Abstract][Full Text] [Related]
24. Using the behaviour change wheel to understand and address barriers to pharmacy naloxone supply in Australia.
Nielsen S; Olsen A
Int J Drug Policy; 2021 Apr; 90():103061. PubMed ID: 33321285
[TBL] [Abstract][Full Text] [Related]
25. Pharmacy naloxone codispensing: A mixed methods study of practices and perspectives under a statewide standing order program.
Pollini RA; Slocum S; Ozga JE; Joyce R; Xuan Z; Green TC; Walley AY
J Am Pharm Assoc (2003); 2022; 62(5):1546-1554. PubMed ID: 35450833
[TBL] [Abstract][Full Text] [Related]
26. Buprenorphine and naloxone access in pharmacies within high overdose areas of Los Angeles during the COVID-19 pandemic.
Dadiomov D; Bolshakova M; Mikhaeilyan M; Trotzky-Sirr R
Harm Reduct J; 2022 Jun; 19(1):69. PubMed ID: 35768817
[TBL] [Abstract][Full Text] [Related]
27. Revisiting pharmacy-based naloxone with pharmacists and naloxone consumers in 2 states: 2017 perspectives and evolving approaches.
Green TC; Donovan E; Klug B; Case P; Baird J; Burstein D; Tapper A; Walley AY; Bratberg J
J Am Pharm Assoc (2003); 2020; 60(5):740-749. PubMed ID: 32334964
[TBL] [Abstract][Full Text] [Related]
28. Impact of a Multicomponent Educational Intervention on Community Pharmacy-Based Naloxone Services Implementation: A Pragmatic Randomized Controlled Trial.
Hohmann LA; Fox BI; Garza KB; Wang CH; Correia C; Curran GM; Westrick SC
Ann Pharmacother; 2023 Jun; 57(6):677-695. PubMed ID: 36047381
[TBL] [Abstract][Full Text] [Related]
29. What is known about community pharmacy supply of naloxone? A scoping review.
Nielsen S; Van Hout MC
Int J Drug Policy; 2016 Jun; 32():24-33. PubMed ID: 26949189
[TBL] [Abstract][Full Text] [Related]
30. Identifying barriers to dispensing naloxone: A survey of community pharmacists in North Carolina.
Rudolph SE; Branham AR; Rhodes LA; Hayes HH; Moose JS; Marciniak MW
J Am Pharm Assoc (2003); 2018; 58(4S):S55-S58.e3. PubMed ID: 30006187
[TBL] [Abstract][Full Text] [Related]
31. Pharmacy leaders' beliefs about how pharmacies can support a sustainable approach to providing naloxone to the community.
Donovan E; Bratberg J; Baird J; Burstein D; Case P; Walley AY; Green TC
Res Social Adm Pharm; 2020 Oct; 16(10):1493-1497. PubMed ID: 31983625
[TBL] [Abstract][Full Text] [Related]
32. Naloxone for opioid overdose prevention: pharmacists' role in community-based practice settings.
Bailey AM; Wermeling DP
Ann Pharmacother; 2014 May; 48(5):601-6. PubMed ID: 24523396
[TBL] [Abstract][Full Text] [Related]
33. Impact of student pharmacist-led naloxone academic detailing at community pharmacies in Texas.
Evoy KE; Groff L; Hill LG; Godinez W; Gandhi R; Reveles KR
J Am Pharm Assoc (2003); 2020; 60(1):81-86. PubMed ID: 31669417
[TBL] [Abstract][Full Text] [Related]
34. Pharmacist attitudes toward pharmacy-based naloxone: A cross-sectional survey study.
Burstein D; Baird J; Bratberg J; Donovan E; Soipe A; Tapper A; Case P; Walley AY; Green TC
J Am Pharm Assoc (2003); 2020; 60(2):304-310. PubMed ID: 31870862
[TBL] [Abstract][Full Text] [Related]
35. "Like it was just everyday business": A qualitative study of pharmacy-based naloxone and syringe customer experience.
Gray M; Shin SS; Silcox J; Flores D; Bolivar D; Irwin AN; Floyd AS; Bratberg J; Boggis JS; Hartung DM; Green TC
J Am Pharm Assoc (2003); 2023; 63(3):838-846. PubMed ID: 36872182
[TBL] [Abstract][Full Text] [Related]
36. Naloxone Co-Dispensing with Opioids: a Cluster Randomized Pragmatic Trial.
Binswanger IA; Rinehart D; Mueller SR; Narwaney KJ; Stowell M; Wagner N; Xu S; Hanratty R; Blum J; McVaney K; Glanz JM
J Gen Intern Med; 2022 Aug; 37(11):2624-2633. PubMed ID: 35132556
[TBL] [Abstract][Full Text] [Related]
37. Naloxone Availability in Retail Pharmacies and Neighborhood Inequities in Access.
Egan KL; Foster SE; Knudsen AN; Lee JGL
Am J Prev Med; 2020 May; 58(5):699-702. PubMed ID: 32005590
[TBL] [Abstract][Full Text] [Related]
38. Factors associated with prescription drug monitoring program utilisation: a cross-sectional survey of community pharmacists.
Picco L; Lam T; Xia T; Nielsen S
Int J Clin Pharm; 2023 Apr; 45(2):421-429. PubMed ID: 36528707
[TBL] [Abstract][Full Text] [Related]
39. Naloxone Availability and Pharmacy Staff Knowledge of Standing Order for Naloxone in Pennsylvania Pharmacies.
Graves RL; Andreyeva E; Perrone J; Shofer FS; Merchant RM; Meisel ZF
J Addict Med; 2019; 13(4):272-278. PubMed ID: 30585876
[TBL] [Abstract][Full Text] [Related]
40. Assessing pharmacists' readiness to dispense naloxone and counsel on responding to opioid overdoses.
Melaragni F; Levy C; Pedrazzi J; Andersen M
J Am Pharm Assoc (2003); 2019; 59(4):550-554.e2. PubMed ID: 31109812
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]